{"analyses":[{"ciPctValue":"95","estimateComment":"Actuarial probability of engraftment at day +100 is calculated according to the product-limit estimate method.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"actuarial probability of engraftment","paramValue":"70"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The number of participants with donor hematopoietic engraftment at day 100 is reported in the data table, and the actuarial probability is calculated using the Kaplan-Meier product-limit estimate statistic, as reported in the statistical analysis section below.","groups":[{"description":"Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic \\[related or unrelated\\] Hematopoietic SCT.\n\nPentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.","id":"OG000","title":"Preparative Regimen of Pentostatin and Alemtuzumab"}],"paramType":"NUMBER","populationDescription":"All participants who completed treatment and underwent allogeneic transplant.","reportingStatus":"POSTED","timeFrame":"Day 100 after transplant.","title":"Actuarial Probability of Donor Hematopoietic Engraftment (Defined as at Least 50% Donor DNA in Bone Marrow at Day 100).","type":"PRIMARY","unitOfMeasure":"participants"}